1. Aderhold C, Faber A, Umbreit C, Birk R, Weiss C, Sommer JU, Hormann K, Schultz JD (2015) Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC. Anticancer Res 35:1951–1959
2. Affolter A, Samosny G, Heimes AS, Schneider J, Weichert W, Stenzinger A, Sommer K, Jensen A, Mayer A, Brenner W, Mann WJ, Brieger J (2017) Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. Head Neck 39:623–632
3. Alsner J, Sorensen SB, Overgaard J (2001) TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol 59:179–185
4. Amin D, Richa T, Mollaee M, Zhan T, Tassone P, Johnson J, Luginbuhl A, Cognetti D, Martinez-Outschoorn U, Stapp R, Solomides C, Rodeck U, Curry J (2020) Metformin effects on FOXP3(+) and CD8(+) T cell infiltrates of head and neck squamous cell carcinoma. Laryngoscope 130:E490–E498
5. Arcaro A, Guerreiro AS (2007) The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics 8:271–306